$93,000 drug sparks debate
The treatment adds 4 months' survival, on average, for men who have incurable prostate tumors. MARILYNN MARCHIONE THE ASSOCIATED PRESS |
Photo by: Elise Amendola Bob Svensson, 80, is hooked up to a blood infusion machine under the care of nurse Nancy Grant at the American Red Cross in Dedham, Mass., as he undergoes a $93,000 prostate cancer treatment. Svensson is honest about why he got it insurance paid. "I would not spend that money," because the benefit doesn't seem worth it.
BOSTON -- Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 per year, sparking fresh debate about how much a few months more of life are worth.
The latest is Provenge, a first-of-a-kind therapy approved in April. It costs $93,000 per year and adds four months' survival, on average, for men with incurable prostate tumors.
Bob Svensson is honest about why he got it -- insurance paid.
"I would not spend that money," because the benefit doesn't seem worth it, says Svensson, 80, a former corporate finance officer from Bedford, Mass.
His supplemental Medicare plan is paying while the government decides whether basic Medicare will cover Provenge and for whom. The tab for taxpayers could be huge -- prostate is the most common cancer in American men. Most of those who have it will be eligible for Medicare, and Provenge will be an option for many late-stage cases. A meeting to consider Medicare coverage is set for Nov. 17.
For the past decade, new cancer-fighting drugs have been topping $5,000 per month. Only a few of these keep cancer in remission so long that they are,
need help?
Even as new cancer treatments offer hope for some, their cost is out of reach for many.
Here is a list of places from which to seek help:
* Genentech: www.Genentech AccessSolutions.com
* Novartis: http://www. patientassistancenow.com
* Patient Advocate Foundation, 800-532-5274 www.patientadvocate.org
* CancerCare, 866-552-6729 www.cancercarecopay.org
* Chronic Disease Fund, 877-968-7233 www.cdfund.org
* Healthwell Foundation, 800-675-8416 www.healthwellfoundation.org
* Leukemia & Lymphoma Society, 877-557-2672 www.LLS.org/copay
* National Organization for Rare Disorders 800-999-6673 www.rarediseases.org
* Patient Access Network Foundation, 866-316-7263 www.panfoundation.org
* Patient Advocate Foundation, 866-512-3861 www.copays.org
* Patient Services Inc., 800-366-7741 www. patientservicesinc.org
in effect, cures. For most people, the drugs may buy a few months or years. Insurers usually pay if Medicare pays. But some people have lifetime caps and more people are uninsured because of job layoffs in the recession.
Unlike drugs that people can try for a month or two and keep using only if they keep responding, Provenge is an all-or-nothing $93,000 gamble. It's a one-time treatment to train the immune system to fight prostate tumors, the first so-called cancer vaccine. Part of why it costs so much is that it's not a pill cranked out in a lab, but a treatment that is individually prepared, using each patient's cells and a protein found on most prostate cancer cells.
When is a drug considered cost-effective?
The most widely quoted figure is $50,000 for a year of life, "though it has been that for decades -- never really adjusted -- and not written in stone," said Dr. Harlan Krumholz, a Yale University expert on health care costs.
Many cancer drugs are way over that mark. Estimates of the cost of a year of life gained for lung cancer patients on Erbitux range from $300,000 to as much as $800,000, said Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer.
Higher costs seem to be more accepted for cancer treatment than for other illnesses, but there's no rule on how much is too much, he said.
June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 December 2020 November 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 December 2017 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008